Next Article in Journal
TOR Signaling Tightly Regulated Vegetative Growth, Conidiation, Oxidative Stress Tolerance and Entomopathogenicity in the Fungus Beauveria bassiana
Previous Article in Journal
The Silent Threat: Antimicrobial-Resistant Pathogens in Food-Producing Animals and Their Impact on Public Health
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 11
Issue 9
10.3390/microorganisms11092128
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Association between the Respiratory Microbiome and Plasma Microbial Extracellular Vesicles in Intubated Patients

by
Jinkyeong Park
1,†,
Seong Ji Woo
2,†,
Yoonki Hong
3,
Jae Jun Lee
2 and
Ji Young Hong
2,4,*
1
Department of Pulmonary, Allergy and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul 05278, Republic of Korea
2
Institute of New Frontier Research Team, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea
3
Department of Internal Medicine, Kangwon National University Hospital, School of Medicine, Kangwon National University, Chuncheon 24289, Republic of Korea
4
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Chuncheon Sacred Heart Hospital, Hallym University Medical Center, Chuncheon 24253, Republic of Korea
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Microorganisms 2023, 11(9), 2128; https://doi.org/10.3390/microorganisms11092128
Submission received: 21 July 2023 / Revised: 17 August 2023 / Accepted: 18 August 2023 / Published: 22 August 2023
(This article belongs to the Special Issue Microbiome and Pneumonia)
Browse Figures
Review Reports Versions Notes

Abstract

:
Extracellular vesicles (EVs) regulate various cellular and immunological functions in human diseases. There is growing interest in the clinical role of microbial EVs in pneumonia. However, there is a lack of research on the correlation between lung microbiome with microbial EVs and the microbiome of other body sites in pneumonia. We investigated the co-occurrence of lung microbiome and plasma microbe-derived EVs (mEVs) in 111 samples obtained from 60 mechanically ventilated patients (41 pneumonia and 19 non-pneumonia cases). The microbial correlation between the two samples was compared between the pneumonia and non-pneumonia cases. Bacterial composition of the plasma mEVs was distinct from that of the lung microbiome. There was a significantly higher correlation between lung microbiome and plasma mEVs in non-pneumonia individuals compared to pneumonia patients. In particular, Acinetobacter and Lactobacillus genera had high correlation coefficients in non-pneumonia patients. This indicates a beneficial effect of mEVs in modulating host lung immune response through EV component transfer.

1. Introduction

Extracellular vesicles (EVs) are small particles released from eukaryotic host cells or pathogens [1]. They have emerged as novel mechanisms for cell-to-cell communication [2], including the transfer of EVs derived from bacteria, which can modulate a host’s innate immunity [3]. EVs are known to be enriched with proteins, lipids DNA and miRNAs [4]. These EV-containing miRNAs are transferred to specific cells and regulate pathogenic processes such as angiogenesis, coagulation and inflammation [5]. EVs released by respiratory pathogens facilitate pro-inflammatory responses of pulmonary epithelium and various immune cells [6]. In parallel, they can induce robust antibody response and reduce bacterial replications, making them promising vaccine candidates [6].
Investigating the microbiome EVs across different body sites can provide comprehensive insights into disease mechanisms and the influence of environmental factors. Recently, increased transfer of gut microbe-derived EVs (mEVs) to the blood has been implicated in the pathogenesis of type 2 diabetes mellitus (T2DM) [7]. However, little is known about the association between plasma mEVs and the respiratory microbiome, particularly in respiratory diseases such as pneumonia. Multiple studies have shown that gut microbiota play an important role in the immune response of the lungs. Additionally, it has been observed that gut mEVs enter the bloodstream, triggering various immune and metabolic reactions [8,9,10,11]. However, it remains unclear whether the respiratory microbiome crosses the alveolar capillary barrier to enter the blood, or if plasma EVs have an effect on the lung microbiome. Further studies are required to clarify the relationship between the respiratory microbiome and plasma mEVs. Therefore, this study analyzed plasma mEVs and respiratory microbiomes in intubated patients and explored the microbial correlation between the two samples. Identifying the association and differences in genomic profiling between respiratory microbiome and plasma mEVs may provide insights into the pathogenesis of pneumonia and the clinical role of plasma mEVs.

2. Materials and Methods

2.1. Study Subjects

This prospective study was conducted at the ICU of Chuncheon Sacred Heart Hospital, South Korea. In total, 120 samples were obtained from 60 subjects who were placed on mechanical ventilation at the time of ICU admission between 18 July 2017, and 15 August 2018 (Figure 1). The exclusion criteria were age < 18 years, initiation of mechanical ventilation ≥ 48 h after ICU admission or mechanical ventilation for <7 days, presence of a neuromuscular disease such as amyotrophic lateral sclerosis and (4) inability to provide informed consent. Endotracheal aspirate (ETA) and plasma samples were collected after > 8 h of fasting. The reasons of mechanical ventilation included the cardiac arrest (n = 4), neurosurgical condition (n = 19), postoperative status (n = 1) and respiratory distress (n = 36). The diagnosis of pneumonia was comprehensively made by physical examination, history taking and radiographic criteria such as chest radiography and chest computed tomography [12]. A diagnosis of pneumonia was made in 41 subjects, followed by treatment based on international guidelines [12,13,14]. Clinical information, including demographic characteristics, presence of acute respiratory distress syndrome (ARDS), severity of illness (Acute Physiology and Chronic Health Evaluation [APACHE] II and Sequential Organ Failure Assessment [SOFA] scores) and clinical outcomes (28-day all-cause mortality, in-hospital mortality and duration of mechanical ventilation), was collected. The study was approved by the Institutional Review Board of Chuncheon Sacred Heart Hospital (approval No. 2017-47). Written informed consent was obtained from the participants, and the study was conducted in accordance with the approved guidelines.

2.2. EV Isolation and DNA Extraction

ETA samples and plasma samples were collected within 7 days of initiating mechanical ventilation. Plasma samples were obtained using BD Vacutainers (BD, Franklin Lakes, NJ, USA) and then centrifuged at 2000× g for 15 min at 4 °C. To isolate the EVs from plasma samples, a microcentrifuge (Labogene 1730R; BMS, Seoul, Republic of Korea) was used to perform differential centrifugation at 10,000× g for 10 min at 4 °C to separate the pellets and supernatant. The supernatant was subsequently filtered through a 0.22 µm filter to eliminate bacteria and foreign particles. Then, the EVs were boiled for 40 min at 100 °C and centrifuged for 30 min at 13,000 rpm and 4 °C. EV DNA extraction was carried out using the DNeasy PowerSoil Kit (Qiagen, Hilden, Germany), and quantification was performed using the QIAxpert system (Qiagen) based on previously described methods. For ETA samples, total DNA extraction was performed using a commercial microbial DNA isolation kit (Qiagen, Hilden, Germany).

2.3. Paired-End Reads Sequencing and Data Processing

The extracted DNA underwent amplification using primers designed to target the V3 to V4 regions of the prokaryotic 16S rRNA gene. V3–V4 is a widely used primer set, targeting different hypervariable regions of the 16S rRNA gene. The primers were: 16S_V3_F (5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3′) and 16S_V4_R (5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVG GGTATCTAATCC-3′). The amplicon library was quantified and subjected to sequencing using the MiSeq platform (Illumina, San Diego, CA, USA), following the manufacturer’s instructions. The paired-end reads were merged using the FLASH software (http://www.cbcb.umd.edu/software/flash), and reads shorter than 350 bp or longer than 550 bp were excluded from further analysis. Chimeric sequences and singletons were removed using VSEARCH and the SILVA gold database. Sequencing reads with >97% similarity were clustered into operational taxonomic units using the SILVA128 database. Samples with low read counts (<150) or failed PCR were excluded for quality control.

2.4. Statistical Analysis

Of 120 samples collected from 60 subjects, 9 samples were excluded due to low read counts and 111 samples were finally used in the analysis. Biodiversity and community similarity analyses were conducted using R software (Version 4.0.4). Alpha and beta diversities were calculated using QIIME. Beta diversity was assessed using the Bray–Curtis dissimilarity index, while alpha diversity was measured using the Chao1 index. Taxa that accounted for >0.5% of the relative abundance were considered predominant. The correlation between the lung microbiome and plasma mEVs was evaluated using Spearman correlations. A permutation-based p-value was calculated from 100,000 permutation replicates, as it is robust for non-normality and small sample sizes. Genera with a correlation coefficient exceeding 0.5 and a false discovery rate less than 0.05 were considered statistically significant.

3. Results

The baseline characteristics of the subjects are presented in Table 1. There were 43 men (71.7%) and 41 people (68.3%) over the age of 65. There were 41 pneumonia cases and 19 non-pneumonia cases. There were no significant differences between the pneumonia and non-pneumonia groups in terms of age, sex, Charlson Comorbidity Index, severity of illness (SOFA and APACHE II scores) and clinical outcomes, including mortality and duration of mechanical ventilation. Inflammatory markers such as CRP and Procalcitonin were significantly higher in the pneumonia group than the non-pneumonia group. As expected, the non-pneumonia group exhibited higher PaO2/FiO2 ratios. Regarding the causes of intubation, neurosurgical conditions and cardiac arrest were more frequently identified in the non-pneumonia group.

3.1. Microbial Diversity between Respiratory Microbiome and Plasma Microbial EVs

Alpha diversity was significantly higher in the ETA samples than in plasma mEVs (Figure 2). The beta-diversity analysis using principal coordinate analysis (pCoA) revealed significant differences between the plasma mEVs and ETA microbiomes at both the phylum and genus levels. At the phylum level, 22 strains were found to be common between the ETA microbiome and plasma mEVs. Proteobacteria, Firmicutes, Actinobacteria, Bacteroidetes and Fusobacteria were the predominant taxa, accounting for >0.5% of the relative abundance.
At the genus level, totals of 898 and 351 genera were identified in the ETA microbiome and plasma mEVs, respectively. Of these, 279 genera were detected in both sampling sites. The microbial taxonomic profiles exhibited significant differences between the ETA microbiome and plasma mEVs (Figure 3). The four most abundant phyla in both the ETA microbiome and plasma mEVs were Proteobacteria, Firmicutes, Actinobacteria and Bacteroidetes. However, Streptococcus and Enterobacter were significantly more abundant in the ETA microbiome than in plasma mEVs, while Staphylococcus, Escherichia-Shigella and Klebsiella were significantly more abundant in plasma mEVs. No genus showed a significantly high correlation between the two sites.

3.2. The 16S rRNA Microbiome

In both pneumonia and non-pneumonia cases, the composition of plasma mEVs was distinct from that of the ETA microbiome, which is consistent with the aforementioned findings in the total 111 samples. The beta-diversity analysis using PCoA revealed significant differences between the plasma mEVs and ETA microbiome in both the pneumonia and non-pneumonia cases (Figure 4, p < 0.001). Taxa that differed in the lung microbiome and plasma mEVs between the pneumonia and non-pneumonia cases were identified. In particular, Corynebacterium and Stenotrophomonas were predominant in the pneumonia group while Prevotella and Alloprevotella were predominant in the non-pneumonia group on lung microbiome analysis. Metagenomics analysis of plasma mEVs demonstrated a significant increase in Cutibacterium in the non-pneumonia group compared to the pneumonia group.
Interestingly, the correlation between the plasma mEVs and ETA microbiome differed significantly between the pneumonia and non-pneumonia cases (Figure 5). Non-pneumonia subjects exhibited a significantly higher correlation compared to the pneumonia patients. The genus-level analysis of the correlation between the ETA microbiome and plasma mEVs revealed that Acinetobacter and Lactobacillus, with correlation coefficients > 0.5 across sampling sites, were associated with non-pneumonia cases. However, there was no genus associated with pneumonia (Table 2).

4. Discussion

Intercellular communication mediated by bacterial EVs is involved in the pathogenesis of lung diseases [2,8]. Previous studies have investigated the migration of EVs derived from gut microbiota to distant sites and their impact on gut permeability [7,11,15]. Emerging evidence suggests the existence of a gut–lung axis, where EVs produced by commensal bacteria in the gut may contribute to mucosal tolerance and protect against lung diseases [16].
However, there is a lack of research on lung microbiome distribution across different body sites and the effects of EVs from other organs on lung inflammation. We found that the lung and plasma microbial communities have distinct compositions and form separate clusters, consistent with previous studies demonstrating weak correlations in the EV composition across different body sites [17,18]. Nah et al. demonstrated that T2DM patients exhibit intestinal permeability dysfunction and higher correlations among stool, serum and urine samples compared to healthy individuals [7]. Based on the increased pulmonary permeability in acute lung injury, such as in ARDS [19], we hypothesized that the correlations between body sites would be lower in healthy subjects compared to pneumonia patients. However, contrary to our expectations, the correlation between the lung microbiome and plasma mEVs was higher in individuals without pneumonia than in pneumonia patients.
We found that the migration of protective bacteria-derived EVs was more likely to increase in the absence of pneumonia, rather than the transfer of EVs derived from respiratory pathogens to the plasma due to increased alveolar-capillary permeability in pneumonia [20].
Macia et al. reported that, under homeostatic conditions, EVs from commensal microbiota suppress pathogenic colonization and regulate the immune response to tolerance [21]. Recent studies have demonstrated that EVs from gram-negative and gram-positive bacteria can have both detrimental and beneficial effects in pneumonia [6].
Outer membrane vesicles (OMVs) interact with the respiratory epithelium and trigger inflammatory responses in the innate and adaptive immune systems during pneumonia [22,23,24,25]. However, OMVs from bacteria, such as B. pertussis, S. pneumoniae, K. pneumoniae and A. baumannii, have also been considered as potential vaccine candidates based on their ability to induce robust antibody responses and beneficial biochemical properties [26,27,28,29].
Several studies have demonstrated that native OMVs from A. baumannii provide protection against clinical isolates, including pan-resistant strains, and reduce mortality [29,30,31,32]. Cai et al. demonstrated that OMVs from A. baumannii can induce dendritic cell activation, promoting Th2 activation and humoral immune responses [33]. Similarly, the increased intercellular communication of Acinetobacter EVs in non-pneumonia cases in our study can be interpreted in terms of the immunogenic and protective potential of EVs.
Our data also revealed that the genus Lactobacillus, with a correlation coefficient > 0.5 between lung and plasma mEVs, was associated with the non-pneumonia status. The beneficial effects of probiotics against infectious diseases are reportedly mediated by probiotic-derived EVs, which inhibit pathogens, enhance barrier function and modulate immunity [34]. Consistent with our findings, previous studies have shown that EVs from different strains of Lactobacillus possess anti-inflammatory properties that are beneficial for hosts [35,36,37].
This study also had some limitations. First, the sample size was relatively small. Second, we were unable to acquire stool samples and could not analyze the microbial community across various body sites. Therefore, we could not confirm whether or not the gut microbiome serves as a major source of plasma microbial EVs. Third, as this study was a cross-sectional clinical study, causality could not be established and the underlying pathophysiological mechanisms could not be fully elucidated. Although some data exist on the beneficial role of mEVs derived from Acinetobacter and Lactobacillus, additional in vivo animal studies are needed to evaluate the migration of microbe-derived EVs across various body sites and their therapeutic effects in pneumonia. Despite these limitations, our study provided a direct comparison between lung microbiome and plasma microbial EVs using human samples, allowing a comprehensive understanding of the microbiome and its communication through EVs.

5. Conclusions

In conclusion, we observed a significantly higher correlation between lung microbiome and plasma EVs in non-pneumonia individuals than in pneumonia patients. This indicates the potential of EVs as a tool for host–bacterial communication. Further large-scale translational studies are warranted to further elucidate the role of microbe-derived EVs across various body sites in pneumonia.

Author Contributions

J.P. researched data and wrote the manuscript. J.J.L. collected samples and researched data. S.J.W. reviewed and edited the manuscript. Y.H. contributed to the discussion and edited the manuscript. J.Y.H. contributed to sample collecting, writing and editing of the manuscript. All authors contributed to the article and approved the submitted version. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF 2020R1A2C1011455 to J.Y.H.), a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry Of Health and Welfare, Republic of Korea (grant number: HI21C1624 to J.Y.H.) and by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. RS-2023-00223501 to J.J.L.). This research was supported by Hallym University Research Fund (J.Y.H.).

Institutional Review Board Statement

The study was approved by the Ethics Committee of Chuncheon Sacred Heart hospital (approval No. 2017-47).

Data Availability Statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found at: (https://www.ncbi.nlm.nih.gov/sra/PRJNA796437, and https://www.ncbi.nlm.nih.gov/sra/PRJNA678854, accessed on 1 August 2023).

Acknowledgments

We wish to thank Tae-Seop Shin and his team at MD Healthcare Inc. for their support in subsequent phylogenetic analyses.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Maas, S.L.N.; Breakefield, X.O.; Weaver, A.M. Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends Cell Biol. 2017, 27, 172–188. [Google Scholar] [CrossRef]
  2. Fujita, Y.; Kadota, T.; Araya, J.; Ochiya, T.; Kuwano, K. Extracellular Vesicles: New Players in Lung Immunity. Am. J. Respir. Cell Mol. Biol. 2018, 58, 560–565. [Google Scholar] [CrossRef] [PubMed]
  3. Schorey, J.S.; Cheng, Y.; Singh, P.P.; Smith, V.L. Exosomes and other extracellular vesicles in host–pathogen interactions. EMBO Rep. 2014, 16, 24–43. [Google Scholar] [CrossRef] [PubMed]
  4. Lee, H.; Zhang, D.; Zhu, Z.; Cruz, C.S.D.; Jin, Y. Epithelial cell-derived microvesicles activate macrophages and promote inflammation via microvesicle-containing microRNAs. Sci. Rep. 2016, 6, 35250. [Google Scholar] [CrossRef] [PubMed]
  5. Lee, H.; Abston, E.; Zhang, D.; Rai, A.; Jin, Y. Extracellular Vesicle: An Emerging Mediator of Intercellular Crosstalk in Lung Inflammation and Injury. Front. Immunol. 2018, 9, 924. [Google Scholar] [CrossRef] [PubMed]
  6. Behrens, F.; Funk-Hilsdorf, T.C.; Kuebler, W.M.; Simmons, S. Bacterial Membrane Vesicles in Pneumonia: From Mediators of Virulence to Innovative Vaccine Candidates. Int. J. Mol. Sci. 2021, 22, 3858. [Google Scholar] [CrossRef]
  7. Nah, G.; Park, S.C.; Kim, K.; Kim, S.; Park, J.; Lee, S.; Won, S. Type-2 Diabetics Reduces Spatial Variation of Microbiome Based on Extracellur Vesicles from Gut Microbes across Human Body. Sci. Rep. 2019, 9, 20136. [Google Scholar] [CrossRef]
  8. Shukla, S.D.; Budden, K.F.; Neal, R.; Hansbro, P.M. Microbiome effects on immunity, health and disease in the lung. Clin. Transl. Immunol. 2017, 6, e133. [Google Scholar] [CrossRef] [PubMed]
  9. Budden, K.F.; Gellatly, S.L.; Wood, D.L.A.; Cooper, M.A.; Morrison, M.; Hugenholtz, P.; Hansbro, P.M. Emerging pathogenic links between microbiota and the gut–lung axis. Nat. Rev. Microbiol. 2016, 15, 55–63. [Google Scholar] [CrossRef]
  10. Romano, M. Gut Microbiota as a Trigger of Accelerated Directional Adaptive Evolution: Acquisition of Herbivory in the Context of Extracellular Vesicles, MicroRNAs and Inter-Kingdom Crosstalk. Front. Microbiol. 2017, 8, 721. [Google Scholar] [CrossRef]
  11. Choi, Y.; Kwon, Y.; Kim, D.-K.; Jeon, J.; Jang, S.C.; Wang, T.; Ban, M.; Jeon, S.G.; Kim, M.-S.; Choi, C.S.; et al. Gut microbe-derived extracellular vesicles induce insulin resistance, thereby impairing glucose metabolism in skeletal muscle. Sci. Rep. 2015, 5, 15878. [Google Scholar] [CrossRef] [PubMed]
  12. Metlay, J.P.; Kapoor, W.N.; Fine, M.J. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997, 278, 1440–1445. [Google Scholar] [CrossRef]
  13. Metlay, J.P.; Waterer, G.W.; Long, A.C.; Anzueto, A.; Brozek, J.; Crothers, K.; Cooley, L.A.; Dean, N.C.; Fine, M.J.; Flanders, S.A.; et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am. J. Respir. Crit. Care Med. 2019, 200, e45–e67. [Google Scholar] [CrossRef]
  14. Kalil, A.C.; Metersky, M.L.; Klompas, M.; Muscedere, J.; Sweeney, D.A.; Palmer, L.B.; Napolitano, L.M.; O’Grady, N.P.; Bartlett, J.G.; Carratala, J.; et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 2016, 63, e61–e111. [Google Scholar] [CrossRef]
  15. Kim, M.-R.; Hong, S.-W.; Choi, E.-B.; Lee, W.-H.; Jeon, S.G.; Jang, M.H.; Gho, Y.S.; Kim, Y.-K. Staphylococcus aureus-derived extracellular vesicles induce neutrophilic pulmonary inflammation via both Th1 and Th17 cell responses. Allergy 2012, 67, 1271–1281. [Google Scholar] [CrossRef] [PubMed]
  16. Choi, Y.; Park, H.; Park, H.S.; Kim, Y.K. Extracellular Vesicles, a Key Mediator to Link Environmental Microbiota to Airway Immunity. Allergy Asthma Immunol. Res. 2017, 9, 101–106. [Google Scholar] [CrossRef] [PubMed]
  17. The Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012, 486, 207–214. [Google Scholar] [CrossRef] [PubMed]
  18. Zhou, Y.; Gao, H.; A Mihindukulasuriya, K.; La Rosa, P.S.; Wylie, K.M.; Vishnivetskaya, T.; Podar, M.; Warner, B.; Tarr, P.I.; Nelson, D.E.; et al. Biogeography of the ecosystems of the healthy human body. Genome Biol. 2013, 14, R1. [Google Scholar] [CrossRef]
  19. Matthay, M.A.; Zemans, R.L. The Acute Respiratory Distress Syndrome: Pathogenesis and Treatment. Annu. Rev. Pathol. Mech. Dis. 2011, 6, 147–163. [Google Scholar] [CrossRef]
  20. Muraca, M.; Putignani, L.; Fierabracci, A.; Teti, A.; Perilongo, G. Gut microbiota-derived outer membrane vesicles: Under-recognized major players in health and disease? Discov. Med. 2015, 19, 343–348. [Google Scholar]
  21. Daou, Y.; Falabrègue, M.; Pourzand, C.; Peyssonnaux, C.; Edeas, M. Host and microbiota derived extracellular vesicles: Crucial players in iron homeostasis. Front. Med. 2022, 9, 985141. [Google Scholar] [CrossRef] [PubMed]
  22. Codemo, M.; Muschiol, S.; Iovino, F.; Nannapaneni, P.; Plant, L.; Wai, S.N.; Henriques-Normark, B. Immunomodulatory Effects of Pneumococcal Extracellular Vesicles on Cellular and Humoral Host Defenses. mBio 2018, 9, e00559-18. [Google Scholar] [CrossRef] [PubMed]
  23. Tiku, V.; Kofoed, E.M.; Yan, D.; Kang, J.; Xu, M.; Reichelt, M.; Dikic, I.; Tan, M.-W. Outer membrane vesicles containing OmpA induce mitochondrial fragmentation to promote pathogenesis of Acinetobacter baumannii. Sci. Rep. 2021, 11, 618. [Google Scholar] [CrossRef] [PubMed]
  24. Athman, J.J.; Sande, O.J.; Groft, S.G.; Reba, S.M.; Nagy, N.; Wearsch, P.A.; Richardson, E.T.; Rojas, R.; Boom, W.H.; Shukla, S.; et al. Mycobacterium tuberculosis Membrane Vesicles Inhibit T Cell Activation. J. Immunol. 2017, 198, 2028–2037. [Google Scholar] [CrossRef] [PubMed]
  25. Vidakovics, M.L.A.P.; Jendholm, J.; Mörgelin, M.; Månsson, A.; Larsson, C.; Cardell, L.-O.; Riesbeck, K. B Cell Activation by Outer Membrane Vesicles—A Novel Virulence Mechanism. PLOS Pathog. 2010, 6, e1000724. [Google Scholar] [CrossRef] [PubMed]
  26. Asensio, C.J.; Gaillard, M.E.; Moreno, G.; Bottero, D.; Zurita, E.; Rumbo, M.; van der Ley, P.; van der Ark, A.; Hozbor, D. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 2011, 29, 1649–1656. [Google Scholar] [CrossRef]
  27. Olaya-Abril, A.; Prados-Rosales, R.; McConnell, M.J.; Martín-Peña, R.; González-Reyes, J.A.; Jiménez-Munguía, I.; Gómez-Gascón, L.; Fernández, J.; Luque-García, J.L.; García-Lidón, C.; et al. Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae. J. Proteom. 2014, 106, 46–60. [Google Scholar] [CrossRef]
  28. Lee, W.-H.; Choi, H.-I.; Hong, S.-W.; Kim, K.-S.; Gho, Y.S.; Jeon, S.G. Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity. Exp. Mol. Med. 2015, 47, e183. [Google Scholar] [CrossRef]
  29. Huang, W.; Zhang, Q.; Li, W.; Chen, Y.; Shu, C.; Li, Q.; Zhou, J.; Ye, C.; Bai, H.; Sun, W.; et al. Anti-outer Membrane Vesicle Antibodies Increase Antibiotic Sensitivity of Pan-Drug-Resistant Acinetobacter baumannii. Front. Microbiol. 2019, 10, 1379. [Google Scholar] [CrossRef]
  30. Pulido, M.R.; García-Quintanilla, M.; Pachón, J.; McConnell, M.J. A lipopolysaccharide-free outer membrane vesicle vaccine protects against Acinetobacter baumannii infection. Vaccine 2019, 38, 719–724. [Google Scholar] [CrossRef]
  31. Huang, W.; Yao, Y.; Long, Q.; Yang, X.; Sun, W.; Liu, C.; Jin, X.; Li, Y.; Chu, X.; Chen, B.; et al. Immunization against Multidrug-Resistant Acinetobacter baumannii Effectively Protects Mice in both Pneumonia and Sepsis Models. PLoS ONE 2014, 9, e100727. [Google Scholar] [CrossRef]
  32. McConnell, M.J.; Rumbo, C.; Bou, G.; Pachón, J. Outer membrane vesicles as an acellular vaccine against Acinetobacter baumannii. Vaccine 2011, 29, 5705–5710. [Google Scholar] [CrossRef] [PubMed]
  33. Cai, W.; Kesavan, D.K.; Cheng, J.; Vasudevan, A.; Wang, H.; Wan, J.; Abdelaziz, M.H.; Su, Z.; Wang, S.; Xu, H. Vesicle-Mediated Dendritic Cell Activation in Acinetobacter baumannii Clinical Isolate, which Contributes to Th2 Response. J. Immunol. Res. 2019, 2019, 2835256. [Google Scholar] [CrossRef] [PubMed]
  34. Dominguez Rubio, A.P.; D’Antoni, C.L.; Piuri, M.; Perez, O.E. Probiotics, Their Extracellular Vesicles and Infectious Diseases. Front. Microbiol. 2022, 13, 864720. [Google Scholar] [CrossRef] [PubMed]
  35. Al-Nedawi, K.; Mian, M.F.; Hossain, N.; Karimi, K.; Mao, Y.-K.; Forsythe, P.; Min, K.K.; Stanisz, A.M.; Kunze, W.A.; Bienenstock, J. Gut commensal microvesicles reproduce parent bacterial signals to host immune and enteric nervous systems. FASEB J. 2015, 29, 684–695. [Google Scholar] [CrossRef] [PubMed]
  36. Li, M.; Lee, K.; Hsu, M.; Nau, G.; Mylonakis, E.; Ramratnam, B. Lactobacillus-derived extracellular vesicles enhance host immune responses against vancomycin-resistant enterococci. BMC Microbiol. 2017, 17, 66. [Google Scholar] [CrossRef]
  37. Seo, M.; Park, E.; Ko, S.; Choi, E.; Kim, S. Therapeutic effects of kefir grain Lactobacillus-derived extracellular vesicles in mice with 2,4,6-trinitrobenzene sulfonic acid-induced inflammatory bowel disease. J. Dairy Sci. 2018, 101, 8662–8671. [Google Scholar] [CrossRef]
Microorganisms 11 02128 g001
Figure 1. The study participants framework.
Figure 1. The study participants framework.
Microorganisms 11 02128 g001
Microorganisms 11 02128 g002
Figure 2. Alpha and beta diversity. (a) Observed OTU and Chao1 alpha-diversity analysis of the subjects for comparison of ETA and plasma samples. (b) The common phyla and genera in both sites. The overlapping circle in the Venn diagram represents the number of common microorganisms in both sites. (c) PCoA analysis visualized on the Bray–Curtis dissimilarity index for beta diversity across body sites.
Figure 2. Alpha and beta diversity. (a) Observed OTU and Chao1 alpha-diversity analysis of the subjects for comparison of ETA and plasma samples. (b) The common phyla and genera in both sites. The overlapping circle in the Venn diagram represents the number of common microorganisms in both sites. (c) PCoA analysis visualized on the Bray–Curtis dissimilarity index for beta diversity across body sites.
Microorganisms 11 02128 g002
Microorganisms 11 02128 g003
Figure 3. Microbial composition at phylum and genus in intubated patients. The numbers indicate the relative proportion of the microbiome of ETA and plasma mEVs.
Figure 3. Microbial composition at phylum and genus in intubated patients. The numbers indicate the relative proportion of the microbiome of ETA and plasma mEVs.
Microorganisms 11 02128 g003
Microorganisms 11 02128 g004
Figure 4. The beta diversity between body sites and microbial composition in pneumonia patients and non=pneumonia individuals. (a) PCoA analysis with the Bray–Curtis dissimilarity index between ETA microbiome and plasma mEV in the pneumonia and non-pneumonia groups. (b) Microbial composition of ETA and plasma mEVs in the pneumonia and non-pneumonia groups.
Figure 4. The beta diversity between body sites and microbial composition in pneumonia patients and non=pneumonia individuals. (a) PCoA analysis with the Bray–Curtis dissimilarity index between ETA microbiome and plasma mEV in the pneumonia and non-pneumonia groups. (b) Microbial composition of ETA and plasma mEVs in the pneumonia and non-pneumonia groups.
Microorganisms 11 02128 g004
Microorganisms 11 02128 g005
Figure 5. Comparison of correlation coefficients between ETA and plasma mEVs based on the pneumonia status. The correlation coefficients were higher in non-pneumonia group than in the pneumonia group. The line indicates the median level.
Figure 5. Comparison of correlation coefficients between ETA and plasma mEVs based on the pneumonia status. The correlation coefficients were higher in non-pneumonia group than in the pneumonia group. The line indicates the median level.
Microorganisms 11 02128 g005
Table 1. Clinical characteristics of the study subjects.
Table 1. Clinical characteristics of the study subjects.
PneumoniaNon-pneumoniap Value
N = 41N = 19
Age 73 (59.5, 80.8)76 (59, 81)0.732
Male30 (73.2%)13 (68.4%)0.763
ARDS8 (19.5%)0 (0%)0.047
Charlson Comorbidity Index3 (1, 4)2 (1, 2)0.051
Reason for intubation <0.001
Cardiac arrest1 (2.4%)3 (15.8%)
Neurosurgical condition5 (12.2%)14 (73.7%)
Postoperative status0 (0%)1 (5.3%)
Respiratory distress35 (85.4%)1 (5.3%)
PaO2/FiO2235.5 (143.8, 304.8)430.8 (321.0, 457.5)<0.001
Severity
APACHE score20 (16,24)22 (17.25)0.165
SOFA score7 (5.8, 9.0)6 (4, 9)0.227
GCS8 (6, 11)6 (5, 9)0.074
28-day mortality12 (29.3%)6 (31.6%)0.99
In-hospital mortality19 (46.3%)6 (31.6%)0.4
MV duration12 (7.8, 18.0)10 (7, 14)0.238
CRP (mg/L)122.5 (44.0, 201.3)61 (4.6, 132.1)0.012
Procalcitonin (ng/mL)0.59 (0.28, 3.32)0.23 (0.04, 0.46)0.012
Data are expressed as median (interquartile range) unless otherwise indicated. PaO2/FiO2: ratio of arterial oxygen partial pressure to fractional inspired oxygen; APACHE: Acute Physiology, Age, Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment; GCS: Glasgow Coma Scale; MV: mechanical ventilation; CRP: C-reactive protein.
Table 2. Significant genera between ETA microbiome and plasma mEV.
Table 2. Significant genera between ETA microbiome and plasma mEV.
SiteGenusCoefficientFDR p-Value
TotalETA-serum EVAcinetobacter0.3680.008
Corynebacterium0.3260.019
Neisseria0.2880.041
Bifidobacterium0.3180.023
Lautropia0.2760.049
PneumoniaETA-serum EVAcinetobacter0.3460.039
Corynebacterium0.3580.032
Alloprevotella−0.0330.049
Non-pneumoniaETA-serum EVAcinetobacter0.6320.013
Lactobacillus−0.5780.024
ETA: endotracheal aspirates, EV: extracellular vesicle.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Park, J.; Woo, S.J.; Hong, Y.; Lee, J.J.; Hong, J.Y. Association between the Respiratory Microbiome and Plasma Microbial Extracellular Vesicles in Intubated Patients. Microorganisms 2023, 11, 2128. https://doi.org/10.3390/microorganisms11092128

AMA Style

Park J, Woo SJ, Hong Y, Lee JJ, Hong JY. Association between the Respiratory Microbiome and Plasma Microbial Extracellular Vesicles in Intubated Patients. Microorganisms. 2023; 11(9):2128. https://doi.org/10.3390/microorganisms11092128

Chicago/Turabian Style

Park, Jinkyeong, Seong Ji Woo, Yoonki Hong, Jae Jun Lee, and Ji Young Hong. 2023. "Association between the Respiratory Microbiome and Plasma Microbial Extracellular Vesicles in Intubated Patients" Microorganisms 11, no. 9: 2128. https://doi.org/10.3390/microorganisms11092128

APA Style

Park, J., Woo, S. J., Hong, Y., Lee, J. J., & Hong, J. Y. (2023). Association between the Respiratory Microbiome and Plasma Microbial Extracellular Vesicles in Intubated Patients. Microorganisms, 11(9), 2128. https://doi.org/10.3390/microorganisms11092128

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop